Stem Cell Therapy Combined with Fetal Surgery Shows Promise for Spina Bifida Treatment
A phase 1 clinical trial published in The Lancet has demonstrated that combining stem cell therapy with standard fetal surgery before birth is a safe and promising approach to treat myelomeningocele, a severe form of spina bifida. This marks the first instance of live stem cells being used to treat a fetus’ damaged spine, potentially leading to improved health outcomes compared to traditional fetal surgery alone.
Understanding Spina Bifida and Current Treatments
Spina bifida is a birth defect that occurs when the spinal cord doesn’t close completely during pregnancy. This can result in a range of lifelong health challenges, including paralysis, difficulty with mobility, and issues with bladder and bowel control. Current treatments typically involve surgery during pregnancy to close the spinal opening, which can reduce some complications but doesn’t always prevent all neurological problems.
The CuRe Trial: A Groundbreaking Approach
The landmark clinical trial, known as the “CuRe Trial: Cellular Therapy for In Utero Repair of Myelomeningocele,” conducted at UC Davis Health, represents a significant advancement in spina bifida treatment. UC Davis Children’s Hospital is leading the research. The trial involved six pregnant women whose fetuses had been diagnosed with spina bifida. These women underwent standard fetal surgery, with an additional step where surgeons applied placenta-derived mesenchymal stem cells (PMSCs) – cells known for their anti-inflammatory, healing, and nerve-protective properties – directly onto the exposed spinal cord during surgery.
Positive Outcomes and Safety Profile
All six babies, born between July 2021 and December 2022, exhibited intact spinal repairs and showed no signs of infection, abnormal tissue growth, or tumor formation. Post-birth MRI scans revealed that brain abnormalities associated with spina bifida, specifically hindbrain herniation, were reversed in every case. The Lancet study confirmed that the stem cell therapy did not interfere with the benefits of fetal surgery and was not associated with any cell-related adverse effects.
Importantly, the infants experienced no serious adverse effects attributable to the stem cell treatment during the trial and through follow-up care. Researchers will continue to monitor the children, with regular check-ups and assessments, until they reach six years of age to confirm the long-term safety and efficacy of the treatment.
Future Directions and Ongoing Research
Additional, larger-scale, long-term clinical trials are currently underway to refine surgical techniques and treatment protocols. These studies aim to confirm that children receiving this therapy experience benefits at birth, improved mobility, and an enhanced quality of life. Regulatory agencies are working closely with the research team to ensure careful monitoring of safety and effectiveness. News-Medical.net reports that this research could pave the way for using stem cells during fetal surgery to address other congenital conditions.
The researchers hope to establish this stem cell therapy as a safe and standard option for fetal repair of spina bifida, offering new hope to families affected by this condition worldwide. MedPage Today highlights that this represents a major milestone in in-utero stem cell treatment for birth defects.
Where to Learn More
To sign up for the CuRe trial or learn more, visit StudyPages or call 1-916-794-2229.